Bayard L. Powell, MD
- Professor, Hematology and Oncology
Bayard L. Powell, MD
Research Interests
- Clinical Research in Acute Leukemia
- Chronic Leukemia
- Myelodysplastic Syndrome
- Education
- MD, University of North Carolina at Chapel Hill School of Medicine, 1980
- Residency
- Wake Forest Baptist Medical Center, 1983
- Board Certifications
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- Memberships
- American College of Physicians
- Cancer and Leukemia Group B (CALGB)
- American Society of Hematology
- American Society of Clinical Oncology
- Association of Medical School Professors of Psychology
- Positions
- Section Chief, Hematology and Oncology
- Medical Director for Medical Oncology, Hematology and Oncology
- Professor, Hematology and Oncology
- Departments and Affiliations
- Hematology and Oncology
- Comprehensive Cancer Center
Research
- Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). Jacoby MA, Finn L, Emadi A, Saba NS, Powell BL, Seiter K, Garcia R, Faderl S, Male HJ. Leuk Lymphoma. 2021 May; :1-4.
- Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Walker CJ, Mrózek K, Ozer HG, Nicolet D, Kohlschmidt J, Papaioannou D, Genutis LK, Bill M, Powell BL, Uy GL, Kolitz JE, Carroll AJ, Stone RM, Garzon R, Byrd JC, Eisfeld AK, de la Chapelle A, Bloomfield CD. Blood Adv. 2021 03; 5(5):1474-1482.
- Efficacy of 10-day decitabine in acute myeloid leukemia. Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Leuk Res. 2021 Apr; 103:106524.
- A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Seegars MB, Woods R, Ellis LR, Bhave RR, Howard DS, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. J Hematol. 2021 Feb; 10(1):1-7.
- SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis. Liu L, Ahmed T, Petty WJ, Grant S, Ruiz J, Lycan TW, Topaloglu U, Chou PC, Miller LD, Hawkins GA, Alexander-Miller MA, O'Neill SS, Powell BL, D'Agostino RB, Munden RF, Pasche B, Zhang W. Mol Oncol. 2021 02; 15(2):462-472.